ResMed Inc. vs VanEck Semiconductor ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while VanEck Semiconductor ETF trades at $603.33 (market cap $73.92B). The key difference: VanEck Semiconductor ETF is far larger — about 2.3× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and VanEck Semiconductor ETF for 101 Days on average.
| RMD | SMH | |
|---|---|---|
Market Cap | $31.89B | $73.92B |
Volume | 618,314 | 11,050,892 |
Sector | Health | — |
52-Week High | $275.96 | $668.91 |
52-Week Low | $182.82 | $325.10 |
Typical Hold Time | 51 Days | 101 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
SMH (VanEck Semiconductor ETF) trades at $606.82, down 2.91% over the past day amid broader market volatility. The ETF maintains a bullish technical signal with strong moving average support, though oscillators are neutral. Recent news highlights semiconductor sector strength, with SMH up approximately 69% year-to-date in 2026, outperforming many individual stocks like Nvidia. The fund provides diversified exposure to chip leaders, benefiting from AI-driven demand and industry consolidation.
Outlook remains positive given structural growth in AI and semiconductor demand, but risks include high concentration in top holdings, sensitivity to tech sector volatility, and geopolitical trade tensions. Investors should weigh the ETF's historical outperformance against potential reversion risks as valuations stretch.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →